Orforglipron

What is Orforglipron?

Orforglipron, branded as Foundayo by Eli Lilly, is the first FDA-approved oral non-peptide GLP-1 receptor agonist (approved April 1, 2026). Unlike injectable GLP-1 agonists (semaglutide, tirzepatide) and even oral semaglutide (which requires SNAC absorption enhancer technology and strict fasting), orforglipron is a small molecule that can be taken as a simple daily tablet without food restrictions. It is technically not a peptide — it's a small molecule that mimics GLP-1 signaling — but it targets the same receptor and belongs to the same therapeutic class as semaglutide and tirzepatide. The FDA approved Foundayo for chronic weight management in adults with obesity, or in adults with overweight plus at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia), as an adjunct to a reduced-calorie diet and increased physical activity. Approval came via the FDA's Commissioner's National Priority Voucher pilot program in just 50 days from filing — the fastest new molecular entity approval since 2002. The approved tablet formulation uses stepped dose titration starting at 0.8 mg once daily and escalating every 30 days to a maximum maintenance dose of 17.2 mg (the Phase 3 trials used 6 mg, 12 mg, and 36 mg capsule doses; the approved tablet doses are different per the PMID 41994902 bioequivalence study). Multiple Phase 3 trials published in the New England Journal of Medicine support the approval (ATTAIN-1 obesity, ATTAIN-2 obesity with T2D, ATTAIN-MAINTAIN weight maintenance, ACHIEVE-1 early T2D).

What Orforglipron Is Investigated For

Orforglipron (Foundayo) is Eli Lilly's FDA-approved oral small-molecule GLP-1 receptor agonist for chronic weight management, with additional studied indications across type 2 diabetes, weight maintenance after injectable GLP-1 therapy, and broader cardiometabolic risk reduction. The strongest evidence is in obesity, with multiple Phase 3 trials published in the New England Journal of Medicine and Nature Medicine — ATTAIN-1 produced 11.2% weight loss at the highest dose over 72 weeks in 3,127 patients, ATTAIN-2 added efficacy in patients with T2D, ATTAIN-MAINTAIN demonstrated weight maintenance after switching from injectable GLP-1 therapy, and ACHIEVE-1 showed glycemic benefit in early T2D. The honest framing on the evidence is that orforglipron is clinically meaningful but produces somewhat less peak weight loss than injectable semaglutide (~14%) and substantially less than tirzepatide (~20%) — its differentiator is convenience (daily pill, no fasting required, no injection), not superior efficacy. The FDA approved Foundayo on April 1, 2026 via the Commissioner's National Priority Voucher pilot program, the fastest NME approval since 2002 (50 days from filing). The approved label covers chronic weight management in adults with obesity, or adults with overweight plus at least one weight-related comorbidity (hypertension, T2D, dyslipidemia). Cardiovascular outcomes data is still pending (no dedicated CVOT equivalent to SELECT or SURPASS-CVOT). Long-term safety beyond the 72-week Phase 3 window remains an open question. T2D as a standalone indication has not yet been approved in the US.

History & Discovery

Orforglipron (Lilly internal designation LY3502970) originated from Chugai Pharmaceutical's small-molecule GLP-1 receptor agonist program and was licensed by Eli Lilly in 2018. Its development is a notable chapter in GLP-1 history because it represents a deliberate attempt to achieve GLP-1 receptor agonism through a non-peptide small-molecule structure — sidestepping the oral bioavailability problem that historically made GLP-1 agonists injection-only, and doing so without the absorption-enhancer workarounds (SNAC technology) required for oral semaglutide. Phase 1 dose-escalation and safety studies were published in 2023. Phase 2 data in obesity and type 2 diabetes, also published in 2023 in the New England Journal of Medicine, established clinically meaningful weight loss and HbA1c reduction and supported advancement to large Phase 3 programs. Between 2024 and early 2026, Lilly reported results across the ACHIEVE series (type 2 diabetes) and ATTAIN series (obesity). ACHIEVE-1 reported positive topline efficacy in early type 2 diabetes in 2025. ATTAIN-1 demonstrated up to 11.2% mean weight loss at 36 mg over 72 weeks in a 3,127-participant obesity cohort. ATTAIN-2 evaluated obesity in people with type 2 diabetes. ATTAIN-MAINTAIN tested whether patients switching from injectable GLP-1s could maintain weight loss on oral orforglipron (published in Nature Medicine, May 2026, PMID 42120723). The regulatory inflection arrived on April 1, 2026, when the FDA approved Foundayo for chronic weight management in adults with obesity, or in adults with overweight plus at least one weight-related comorbidity (hypertension, T2D, dyslipidemia), as an adjunct to a reduced-calorie diet and increased physical activity. The approval came through the FDA's Commissioner's National Priority Voucher pilot program — 50 days from filing to approval, the fastest new molecular entity (NME) approval since 2002. The approved label carries the GLP-1-class boxed warning for thyroid C-cell tumors (contraindication in personal or family history of MTC or MEN 2). Foundayo's commercial formulation is a tablet (distinct from the Phase 3 capsule), with stepped dose titration starting at 0.8 mg once daily and escalating every 30 days to a maximum maintenance dose of 17.2 mg — supported by the PMID 41994902 bioequivalence study comparing tablet and capsule formulations. Foundayo entered the US market in April 2026 at approximately $149/month self-pay for the lowest dose, with $25/month commercial savings card pricing and Medicare Part D access at $50/month from July 1, 2026. Foundayo is the first FDA-approved oral non-peptide GLP-1 receptor agonist — a meaningful milestone for oral incretin therapy, particularly versus the SNAC-dependent oral semaglutide formulation (Rybelsus). International regulatory submissions (EMA, MHRA, Health Canada, PMDA) are at various stages of review as of mid-2026.

How It Works

Foundayo (orforglipron) is a pill that mimics the GLP-1 hormone — the same target as Ozempic and Mounjaro. It tells your brain you're full, slows stomach emptying, and helps your body manage blood sugar. The breakthrough is that it's a small molecule rather than a peptide, so it survives digestion and can be taken as a simple daily pill.

Orforglipron is a non-peptide, small-molecule agonist of the GLP-1 receptor. Unlike peptide-based GLP-1 agonists that require injection or specialized oral delivery technology (SNAC for oral semaglutide), orforglipron's small-molecule structure confers oral bioavailability without absorption enhancers. It activates the GLP-1 receptor on pancreatic beta cells (enhancing glucose-dependent insulin secretion), hypothalamic appetite centers (reducing food intake), and gastric smooth muscle (slowing gastric emptying). Phase 3 data from ATTAIN-1 (3,127 participants, 72 weeks) demonstrated dose-dependent weight loss: -7.5% (6 mg), -8.4% (12 mg), and -11.2% (36 mg) vs -2.1% placebo. At 36 mg, 54.6% achieved at least 10% weight loss and 18.4% achieved at least 20%. Secondary improvements included waist circumference, systolic blood pressure, triglycerides, and non-HDL cholesterol. The ATTAIN-MAINTAIN trial demonstrated successful weight maintenance when patients switched from injectable GLP-1s to oral orforglipron.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Orforglipron:

• 01Cardiovascular outcomes — a dedicated cardiovascular outcomes trial (CVOT) equivalent to semaglutide's SELECT or tirzepatide's SURMOUNT-CVD has not been completed for orforglipron. CVOT data is typically required for GLP-1 labels extending beyond glycemic control, and orforglipron's positioning on cardiovascular risk reduction will depend on forthcoming trial readouts.
• 02Long-term safety beyond the 72-week Phase 3 window — chronic use data beyond trial duration does not yet exist, and GLP-1 agonists are chronic therapies for obesity and T2D.
• 03Head-to-head versus injectable GLP-1 and GLP-1/GIP agonists — direct comparative efficacy versus semaglutide 2.4 mg and tirzepatide is not established in randomized comparisons; existing comparisons are cross-trial.
• 04Pediatric and adolescent efficacy and safety — not yet studied.
• 05Effect on longer-term metabolic health markers (lean mass preservation, bone density, non-alcoholic fatty liver disease endpoints) — these are active questions across the GLP-1 class and not yet fully resolved for orforglipron.
• 06Real-world adherence and discontinuation dynamics — trial-setting adherence typically exceeds real-world adherence, and how orforglipron's oral-without-food-restrictions profile translates to real-world persistence is not yet known.

Forms & Administration

Orforglipron is taken as a once-daily oral tablet (Foundayo). The approved label uses stepped dose titration starting at 0.8 mg once daily, with escalation every 30 days to a maintenance dose up to 17.2 mg max. Note: this differs from the Phase 3 trial dosing (6 mg, 12 mg, and 36 mg capsules) because the approved commercial formulation is a tablet with different pharmacokinetics — the PMID 41994902 bioequivalence study supported the tablet-formulation dose conversion. The tablet does not require fasting or special administration conditions. Pricing (US, as of April 2026 launch): approximately $149/month self-pay at lowest dose; $25/month with commercial savings card; $50/month Medicare Part D starting July 1, 2026.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

These doses reflect the FDA-approved Foundayo label as of April 2026. Foundayo is a prescription medication and should be used under the supervision of a qualified healthcare provider. The trial-era capsule doses (6/12/36 mg) circulating in older orforglipron coverage do not match the approved tablet label.

Timeline of Effects

Common Questions

Who Orforglipron Is NOT For

Drug & Supplement Interactions

Orforglipron's small-molecule structure means its interaction profile is different from peptide GLP-1 agonists in important ways, but several class-level concerns still apply. Gastric emptying is delayed by GLP-1 receptor activation, which can alter the absorption of concomitant oral medications — particularly those with narrow therapeutic windows or rapid-onset requirements. Patients taking oral medications requiring rapid absorption (such as certain hypnotics, analgesics, or emergency medications) should be aware that onset timing may shift. Concurrent use with other glucose-lowering agents, particularly sulfonylureas and insulin, increases hypoglycemia risk and typically requires dose adjustment of those agents. As a cytochrome-P450-metabolized small molecule, orforglipron may have CYP-level interactions that peptide GLP-1 agonists do not, and Lilly's Phase 1 program included dedicated interaction studies. Specific clinically relevant CYP interactions will be defined in the eventual product label; until then, patients on complex medication regimens should disclose any orforglipron exposure (including trial participation) to their prescribing clinicians. Concurrent use with other GLP-1 receptor agonists or dual agonists (tirzepatide, semaglutide, liraglutide) is not clinically indicated and would compound both efficacy and adverse-event profile.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions